{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"157.53","value":"14.00"},{"groupId":"OG001","spread":"189.70","value":"12.88"}]}],"title":"Cycle 1 (n = 198, 193)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"145.36","value":"30.13"},{"groupId":"OG001","spread":"124.50","value":"40.00"}]}],"title":"Cycle 2 (n = 197, 190)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"110.35","value":"45.25"},{"groupId":"OG001","spread":"101.83","value":"63.83"}]}],"title":"Cycle 3 (n = 192, 190)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"108.90","value":"54.06"},{"groupId":"OG001","spread":"92.28","value":"81.71"}]}],"title":"Cycle 4 (n = 186, 185)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"89.90","value":"64.68"},{"groupId":"OG001","spread":"71.91","value":"98.00"}]}],"title":"Cycle 5 (n = 185, 185)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.60","value":"71.02"},{"groupId":"OG001","spread":"58.74","value":"109.56"}]}],"title":"Cycle 6 (n = 187, 180)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.76","value":"78.31"},{"groupId":"OG001","spread":"55.60","value":"120.75"}]}],"title":"Cycle 7 (n = 183, 172)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.53","value":"77.60"},{"groupId":"OG001","spread":"50.20","value":"131.48"}]}],"title":"Cycle 8 (n = 52, 54)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"description":"Stage I and II (Induction): Rituximab IV: Predose (within 2 hr) on D1 of Cy1-8 (1 Cy=3 weeks \\& 4 weeks for Cy8); Rituximab SC: Predose (within 2 hr) on D1 of Cy1 \\& Cy3-8 (1 Cy=3 weeks and 4 weeks for Cy8), predose (within 2 hr) on D0 of Cy2 (up to data cutoff of 31 Oct 2013 \\[up to 32 months\\])","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"ITT Population. Here, number of participants analyzed = participants evaluable for the outcome measure. Here \"n\" = number of participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Stage I and II (Pooled): Predose (within 2hr) up to data cutoff of 31 Oct 2013 [up to 32 months]) (See detailed timeframe in Outcome Measure description)","title":"Stage I and II (Pooled): Ctrough of Rituximab at Each Induction Treatment Cycle","type":"SECONDARY","unitOfMeasure":"mcg/mL"}